Intel (INTC) Stock Analysis

Intel continued to state that it intended to complete Fab 34, but explicitly acknowledged expected near-term construction delays. Because the contractual completion deadline had not yet passed, the commitment remains active and unconfirmed. (1 in progress, 1 not yet due, 1 revised across 3 tracked commitments)

The commercial CHIPS Act agreement was materially amended. Intel received $5.7 billion of accelerated remaining disbursements, while prior project milestones and substantially all other agreement requirements were removed. The filing also reports $1.0 billion of CHIPS Act grants recognized year-to-date, but the original grant-based structure was replaced in part by equity issuance. (1 revised, 1 in progress across 2 tracked commitments)

Release the first SKU manufactured on Intel 18A. — target: First SKU of Intel 18A-manufactured products

Management plans to continue investing in process technology and product roadmaps, worldwide manufacturing and assembly/test operations, and future manufacturing expansion. (+2 more commitments)

Management expects R&D and MG&A expenses to decline in 2026 versus recent historical periods as a result of restructuring, cost-reduction measures, and the Altera deconsolidation. — target: Total R&D and MG&A expenses to decrease in 2026 relative to recent historical periods

All Other expanded materially year to date, helped by Mobileye and other non-reportable businesses. Revenue grew 20.1%, from $2.488B to $2.989B, and the category moved from an operating loss to operating income. Mobileye revenue rose 25.6% year to date, while Q3 Mobileye revenue increased 3.7%. The category became profitable, although the eventual deconsolidation of 51% of Altera changes its composition. (2 expanding, 2 shifted)

The nature of Intel Foundry shifted from primarily an internal manufacturing function toward a potential external customer business. Intel 18A entered high-volume production and was positioned as a node for government and enterprise customers, while Intel 14A was designed from inception for external customers. However, Intel stated that it may pause or discontinue Intel 14A and later nodes if it cannot secure a significant external customer. (2 shifted, 2 expanding)

DCAI's AI accelerator position remained weak despite broader data-center growth. Intel recognized $375 million of Gaudi AI accelerator inventory-related charges in FY2025, down from $922 million in FY2024. The lower charge is an improvement, but it still indicates unsuccessful accelerator commercialization relative to NVIDIA and AMD. (1 shifted)

Intel Foundry's reported revenue increased slightly, but the business remained overwhelmingly internal rather than an external foundry. External revenue increased from $159 million to $307 million, yet represented only about 0.6% of consolidated revenue in FY2025. The segment remained deeply loss-making because of manufacturing investment, depreciation, and early Intel 18A ramp costs. (2 expanding, 1 contracting, 2 shifted)

Intel Foundry remained overwhelmingly an internal manufacturing operation rather than an external foundry business. External revenue fell 41.8% year over year in Q3 and 20.6% year to date, while total segment revenue grew 2.6% year to date almost entirely because of higher intersegment revenue. The segment remained deeply loss-making, although the loss rate improved as Intel lapped major manufacturing-asset impairments and reduced operating expenses. (1 shifted across 1 engine)

No concrete purpose-built silicon or ASIC revenue figure is disclosed in this filing. The document discusses AI accelerators, including Gaudi 3, but does not provide a separate revenue series that can be tracked across quarters. (2 discontinued, 1 accelerating across 3 signals)

The previously extracted customer-deposit signal is not present in this filing. No customer deposits for future supply are disclosed, so there is no current-period evidence to support continuation of that traction signal. (1 discontinued, 1 reversing, 2 new trend across 4 signals)

External foundry revenue remains extremely small and declined year over year: $32 million in Q3 and $85 million year to date, versus $55 million and $107 million in the comparable 2024 periods. This is a reversal rather than evidence of a scaling external-customer business. (1 reversing across 1 signal)

The filing does not report the previously cited $1.7 billion of customer deposits for future supply. The available Q1 2025 filing instead discloses $800 million of receivables sold to financial institutions, which is a liquidity action rather than customer prepayment. The customer-deposit growth signal is therefore not confirmed in this quarter and should be treated as discontinued for this document. (4 discontinued across 4 signals)

Intel invested $5.183 billion in property, plant, and equipment in Q1 2025, down 13% from $5.970 billion in Q1 2024, while receiving $803 million of capital-related government incentives versus $592 million. Capital spending remains very large, but the year-over-year decline suggests a decelerating investment pace as Intel manages its manufacturing buildout. (1 decelerating across 1 signal)

The risk was present but showed mixed evidence in Q3 FY25. Year-to-date CCG revenue fell 2%, client revenue fell $605 million, and lower customer inventory levels contributed to lower volumes. CCG operating income declined $1.3 billion year to date, while higher costs and inventory reserves pressured profit. Q3 demand improved, with client revenue up $383 million and volume higher, but the filing did not establish a durable recovery. The Jun. 2026 baseline later showed a sharper deterioration, with client volumes down 8% in Q2 and 10% year to date despite higher selling prices. Severity therefore increased from MEDIUM in Q3 FY25 to HIGH in the later baseline. (2 intensifying, 1 stable, 1 high-severity)

This execution risk was concrete and high in Q3 FY25. Intel required a significant external customer for Intel 14A and acknowledged that failure to secure one could make development uneconomic. External Foundry revenue was only $32 million in Q3 and $85 million year to date, while nearly all Foundry revenue came from Intel internal business. By the Jun. 2026 baseline, the risk had intensified: Intel was still committing to Intel 14A and expanding manufacturing before securing sufficient external demand. Accordingly, severity increased from HIGH in Q3 FY25 to HIGH in the later baseline, but the risk became more clearly entrenched rather than improving. (1 intensifying, 1 high-severity)

The risk emerged in Q3 FY25 and was already material. Intel received $5.7 billion of accelerated government funding while issuing 275 million shares, placing 159 million additional shares into escrow, and granting warrants for up to 241 million shares at $20. The escrowed-share liability reached $5.6 billion and generated a $1.7 billion mark-to-market loss in Q3. Intel also warned that the SEC could require materially different accounting and that the U.S. government held approximately 5.8% of the company, with potential additional ownership. The Jun. 2026 baseline showed a much larger $12.529 billion mark-to-market loss and a $15.570 billion escrow liability. Severity therefore increased from HIGH in Q3 FY25 to HIGH but substantially more financially significant in the later baseline. (3 intensifying, 1 stable, 1 high-severity)

EASING. In FY2025, CCG client revenue fell $1.1 billion, client volume declined, and customers reduced inventories. However, customers normalized inventory through Q3, while Q4 supply constraints caused Intel to miss demand rather than suffer solely from weak end demand. The Jun 2026 baseline introduced a new concern that demand could weaken once shortages ease, but the available later evidence still showed strong pricing and demand. Accordingly, the earlier inventory-correction risk improved, although it was replaced by a potential post-shortage demand risk. (1 easing, 1 high-severity)

This was a high-severity operational risk in Q3 FY25. Intel stated that a significant portion of revenue came from products manufactured on Intel 7 in Israel, that hostilities had escalated, and that it was not insured for business interruption caused by war or political violence. No material interruption had occurred by the filing date, but a shutdown could have a significant adverse effect. The Jun. 2026 baseline continued to identify this as an unusually severe and uninsured risk, with no evidence that insurance or geographic dependence had materially improved. Severity remained HIGH. (1 stable, 2 emerging, 3 high-severity)